# Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

> **NCT04070443** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 170 (estimated)

## Conditions studied

- Philadelphia Chromosome Positive CML
- BCR-ABL Positive Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Ponatinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT04070443
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-13
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070443, "Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04070443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*